OBJECTIVES/HYPOTHESIS: The purpose of this study was to determine whether concomitant chemoradiation (CCRT)-induced hearing loss is progressive over time or not. STUDY DESIGN: Long-term (LT) follow-up study. METHODS: Between 1999 and 2004, 158 patients with head and neck cancer were treated with intravenous (IV) CCRT (n = 80) or intraarterial CCRT (n = 78). Audiometry was performed before, short-term (ST), and LT posttreatment. Differences in hearing were assessed with a multivariable linear regression analysis, incorporating the effect of aging. RESULTS: Long-term audiometry (median 4.5 years) was available in 67 patients (42%). At ST follow-up, a deterioration of 21.6 decibel was seen compared to baseline at pure-tone averages (PTA) 8-10-12.5 kHz. At LT follow-up, this deterioration further increased with 5 decibel (P = 0.005). Only in CCRT-IV patients was a significant progressive treatment-induced hearing loss seen, at PTA 8-10-12.5 kHz (P = 0.005), PTA 1-2-4 kHz air conduction (P = 0.014), and PTA 0.5-1-2 kHz bone conduction (P = 0.045). CONCLUSION: CCRT-induced hearing impairment was progressive over time, especially in higher frequencies and only in CCRT-IV patients, with a modest deterioration of 5 decibel 4.5 years post-treatment. LEVEL OF EVIDENCE: 4.
OBJECTIVES/HYPOTHESIS: The purpose of this study was to determine whether concomitant chemoradiation (CCRT)-induced hearing loss is progressive over time or not. STUDY DESIGN: Long-term (LT) follow-up study. METHODS: Between 1999 and 2004, 158 patients with head and neck cancer were treated with intravenous (IV) CCRT (n = 80) or intraarterial CCRT (n = 78). Audiometry was performed before, short-term (ST), and LT posttreatment. Differences in hearing were assessed with a multivariable linear regression analysis, incorporating the effect of aging. RESULTS: Long-term audiometry (median 4.5 years) was available in 67 patients (42%). At ST follow-up, a deterioration of 21.6 decibel was seen compared to baseline at pure-tone averages (PTA) 8-10-12.5 kHz. At LT follow-up, this deterioration further increased with 5 decibel (P = 0.005). Only in CCRT-IV patients was a significant progressive treatment-induced hearing loss seen, at PTA 8-10-12.5 kHz (P = 0.005), PTA 1-2-4 kHz air conduction (P = 0.014), and PTA 0.5-1-2 kHz bone conduction (P = 0.045). CONCLUSION: CCRT-induced hearing impairment was progressive over time, especially in higher frequencies and only in CCRT-IV patients, with a modest deterioration of 5 decibel 4.5 years post-treatment. LEVEL OF EVIDENCE: 4.
Authors: Lori Zitelli; Catherine Palmer; Elizabeth Mamula; Jonas Johnson; Grant Rauterkus; Marci L Nilsen Journal: J Cancer Surviv Date: 2022-03-29 Impact factor: 4.442
Authors: Johnnie K Bass; Chia-Ho Hua; Jie Huang; Arzu Onar-Thomas; Kirsten K Ness; Skye Jones; Stephanie White; Shaum P Bhagat; Kay W Chang; Thomas E Merchant Journal: J Clin Oncol Date: 2016-01-25 Impact factor: 44.544
Authors: Lauren K Dillard; Lucero Lopez-Perez; Ricardo X Martinez; Amanda M Fullerton; Shelly Chadha; Catherine M McMahon Journal: Cancer Epidemiol Date: 2022-06-17 Impact factor: 2.890